1. Home
  2. PRAX vs ACT Comparison

PRAX vs ACT Comparison

Compare PRAX & ACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$263.71

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Enact Holdings Inc.

ACT

Enact Holdings Inc.

HOLD

Current Price

$42.61

Market Cap

6.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
ACT
Founded
2015
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Specialty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
6.0B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
PRAX
ACT
Price
$263.71
$42.61
Analyst Decision
Strong Buy
Buy
Analyst Count
15
4
Target Price
$572.13
$44.25
AVG Volume (30 Days)
427.5K
258.9K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
1.90%
EPS Growth
N/A
3.43
EPS
N/A
1.18
Revenue
N/A
$1,235,827,000.00
Revenue This Year
N/A
$4.06
Revenue Next Year
$7,758.26
$2.33
P/E Ratio
N/A
$35.62
Revenue Growth
N/A
2.83
52 Week Low
$37.25
$33.94
52 Week High
$366.52
$44.80

Technical Indicators

Market Signals
Indicator
PRAX
ACT
Relative Strength Index (RSI) 39.24 53.20
Support Level $157.29 $41.98
Resistance Level $342.62 $42.80
Average True Range (ATR) 21.68 0.80
MACD -6.71 0.07
Stochastic Oscillator 20.77 76.01

Price Performance

Historical Comparison
PRAX
ACT

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About ACT Enact Holdings Inc.

Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.

Share on Social Networks: